Undisclosed PD-L1 mAb / JSR Life Sciences - LARVOL DELTA

Establishment and application of a panel of PBMC-humanized mouse tumor models in immune-oncology and targeted cancer immunotherapy (AACR 2018) - "...Besides the success of anti-PD-1 and anti-PD-L1 antibodies (such as Keytrude and Tecentriq), two bispecific antibodies, Catumaxomab and Blinatumomab have been approved to treat cancer patients, and many more bispecific antibodies are currently in pre-clinical or clinical development... MiXenoTM tumor models with specific tumor antigen targeting strategy are valid model systems to evaluate the human immuno-modulatory drugs including bispecific antibodies. Further studies are needed to expand model collections and to extend their applications in I/O space."

IO Biomarker • PD(L)-1 Biomarker • Preclinical • Oncology

Commensal microbiota is involved in anti-PD-1 mAb-mediated antitumor activity in a preclinical tumor model (AACR 2018) - "Upon further characterization and confirmation, these intriguing findings could lead to identification of one or more microbiota strains that could have biomarker potentials or therapeutic values for cancer immunotherapy."

IO Biomarker • PD(L)-1 Biomarker • Preclinical • Oncology

3D ex vivo PDX cell model screening to better predict in vivo outcome (AACR 2018) - "The data will be presented. In summary, we have developed a robust and reproducible 3D ex vivo assay platform for medium-throughput compound screening with bioinformatics information for data interpretation."

IO Biomarker • Oncology